Tamer A. Al-Shafie

Prof. Dr. Tamer A. Al-Shafie

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Closed access
PDF file
HHHala M. Hatab
Hala M. Hatab
FHFatma F. Abdel Hamid
Fatma F. Abdel Hamid
ASAhmed F Soliman
Ahmed F Soliman
TATamer A. Al-Shafie
Tamer A. Al-Shafie
YIYahia M. Ismail
Yahia M. Ismail
MEMotawa E. El-Houseini
Motawa E. El-Houseini
Background: Investigating and evaluating possible alternative therapeutic strategies to control hepatocellular carcinoma (HCC) is a critical need because of its high prevalence and being one of the most lethal cancers. Curcumin and taurine showed potent anti-tumor activities in pre-clinical and clinical studies by targeting multiple pathways. Thus, this study was designed to assess the effect of a combined treatment consisted of curcumin, piperine, and taurine on circulating levels of interleukin-10 (IL-10), and microRNAs miR-141 and miR-21. Methods: Twenty eligible HCC patients administrated an oral dose of 4 g curcumin, 40 mg piperine, and 500 mg taurine daily for three successive treatment cycles, each was a 30-day. The level of IL-10 along with the expression levels of miR-141, and miR-21 were monitored in serum before starting the treatment and after each cycle. Patients were followed-up for a period of 24 months. Results: The combined treatment was able to produce a significant decrease in the levels of serum IL-10, and miR-21 while it resulted in a non-significant up-regulation of serum miR-141 expression level. At the end of the follow-up period, the median overall survival (OS) rate was found to be 17.00 months with a worse OS in patients with high baseline levels of circulating IL-10 and miR-21 compared to those with low levels. In contrast, a low baseline level of circulating miR-141 was associated with poor prognosis. Conclusions: The combined treatment may be able to increase the OS rate by altering the circulating level of IL-10 and miR-21.

24 June 2020 in Nutrition and Cancer
Verified
Journal Article
Closed access
AAAbdel-Hady A. Abdel-Wahab
Abdel-Hady A. Abdel-Wahab
HEHeba Effat
Heba Effat
EMEngy A. Mahrous
Engy A. Mahrous
MAMennatallah A. Ali
Mennatallah A. Ali
TATamer A. Al-Shafie
Tamer A. Al-Shafie
Targeting altered metabolism in cancer provides a promising preventive and therapeutic approach. Natural products interplay between gene expression and metabolism either by targeting altered metabolic enzymes and/or affecting the regulating miRNAs. Licorice is a widely known product used as flavoring agent. Glycyrrhizin and other metabolites were reported to exert several metabolic benefits. Here, we investigated the effect of licorice roots extract on some metabolic pathways and their regulating miRNAs in hepatocellular carcinoma cells. Our data showed various beneficial effects of licorice roots extract including induction of apoptosis and cell cycle arrest. Second, upregulating tumor suppressor miRNAs; let7a-3p, miR-34c-5p, miR-122-5p, miR-126-3p, miR195-5p, miR-199a-5p, miR-206, and miR-326-5p. Third, inhibiting HIF1α, PI3K and C-Myc and activating AMPK and p53. Fourth, inhibiting enzymes of glycolysis; HK-2, LDH-A and PK-M2; pentose phosphate pathway; G6PD and glutaminolysis; glutaminase. However, such an extract upregulated oncogenic miRNAs; miR-21, miR-221, and miR-222. Although the present data highlights the ability of licorice roots extract to enhance apoptosis and cell cycle arrest and correct altered metabolism, it warns against its unfavorable effects, hence, its use for prevention and therapy should proceed with caution. Further experiments are required to investigate whether a specific bioactive ingredient is responsible for upregulating the oncogenic miRNAs.

15 August 2019 in Biochemistry (Moscow)
Verified
Journal Article
Closed access
MEM. E. El-Houseini
M. E. El-Houseini
AIA. Ismail
A. Ismail
AAA. A. Abdelaal
A. A. Abdelaal
AEA. H. El-Habashy
A. H. El-Habashy
ZAZ. F. Abdallah
Z. F. Abdallah
TATamer A. Al-Shafie
Tamer A. Al-Shafie
Transforming growth factor beta (TGF-β) acts as a tumor-suppressing cytokine in healthy tissues and non-malignant tumors. Yet, in malignancy, TGF-β can exert the opposite effects that can promote proliferation of cancer cells. C-Kit plays a prominent role in stem cell activation and liver regeneration after injury. However, little is known about the cross-talk between TGF-β and C-Kit and its role in the progression of hepatocellular carcinoma (HCC). Here, we studied the effect of increasing doses of TGF-β1 on CD44+CD90+ liver stem cells (LSCs) and C-Kit gene expression in malignant and adjacent non-malignant liver tissues excised from 32 HCC patients. The percentage of LSCs in malignant tumors was two times higher compared to their counterparts from the non-malignant tissues. When treated with increasing doses of TGF-β1, proliferation of both malignant and non-malignant LSCs was progressively suppressed, but low TGF-β1 dose failed to suppress the growth of malignant LSCs. Moreover, C-Kit exons 9 and 11 were expressed in malignant LSCs, but not in their non-malignant counterparts. Analysis of C-Kit detected mutations in exon 9 (but not in exon 11) in some malignant liver cells resulting in the changes in the amino acid sequence and dysregulation of protein structure and function. Interestingly, in malignant liver cells, mutations in exon 9 were associated with high-viremia hepatitis C virus (HCV), and expression of this exon was not suppressed by the TGF-β1 treatment at all doses. To our knowledge, this is the first report that mutations in the C-Kit gene in HCC patients are associated with high- viremia HCV. Our study emphasizes the need for investigation of the TGF-β1 level and C-Kit mutations in patients with chronic HCV for HCC prevention and better therapy management.

16 February 2023 in Toxics
Verified
Journal Article
Open access
PDF file
TATamer A. Al-Shafie
Tamer A. Al-Shafie
EMEngy A. Mahrous
Engy A. Mahrous
Mustafa ShukryMustafa Shukry
Mustafa Shukry
MAMohammad alshahrani
Mohammad alshahrani
SISamah Ibrahim
Samah Ibrahim
MAMennatallah A Ali
Mennatallah A Ali
Increasing cancer cell sensitivity to chemotherapy by amending aberrant metabolism using plant extracts represents a promising strategy to lower chemotherapy doses while retaining the same therapeutic outcome. Here, we incubated HepG2 cells with four plant extracts that were selected based on an earlier assessment of their cytotoxicity, viz asparagus, green tea, rue, and avocado, separately, before treatment with doxorubicin. MTT assays elucidated a significant decrease in doxorubicin-IC50 following HepG2 incubation with each extract, albeit to a variable extent. The investigated extract’s ultra-performance liquid chromatography and gas chromatography coupled with mass spectrometry (UPLC/MS and GC/MS) revealed several constituents with anticancer activity. Biochemical investigation displayed several favorable effects, including the inhibition of hypoxia-inducible factor1α (HIF1α), c-Myc, pyruvate kinase-M2 (PKM2), lactate dehydrogenase-A (LDH-A), glucose-6-phosphate dehydrogenase (G6PD), and glutaminase by asparagus and rue extracts. To less extent, HIF1α, c-Myc, PKM2, and LDH-A were partially inhibited by green tea extract, and HIF1α and glutaminase activity was inhibited by avocado oil. Undesirably, green tea extract increased glutaminase; avocado oil rose c-Myc, and both increased G6PD. In conclusion, our study confirms the potential cytotoxic effects of these plant extracts. It highlights a strong association between the ability of asparagus, green tea, rue, and avocado to sensitize HepG2 cells to doxorubicin and their power to amend cell metabolism, suggesting their use as add-on agents that might aid in clinically lowering the doxorubicin dose.

28 March 2022 in Egyptian Journal of Chemistry
Verified
Journal Article
Closed access
EAEsraa A. Aidy
Esraa A. Aidy
ZFZeinab Fathy
Zeinab Fathy
WAWafaa Abdullah Ahmed
Wafaa Abdullah Ahmed
SESaad El-Gendy
Saad El-Gendy
AAAmany Abou-Bakr
Amany Abou-Bakr
TATamer A. Al-Shafie
Tamer A. Al-Shafie
Unlike differentiated cells, cancer stem cells (CSCs) can generate malignancy. Conventional chemotherapy results in CSCs spreading causing metastasis and relapse. Differentiation is an emerging approach providing a safer strategy to eradicate CSCs. Jasonia montana is a medicinal plant that occurs in Sinai Peninsula in Egypt. Here, we used two human colorectal cancer cell lines; HCT-116 and Caco-2 to investigate the ability of methanolic and petroleum ether extracts of Jasonia montana to differentiate colon CSCs. Tandem Mass–Spectrometry (MS/MS) revealed that quercitrin and 5-Hydroxycostic acid represent the major extracts ingredients. Cytotoxicity assay (SRB) illustrated that petroleum ether extract inhibited Caco-2 cells (IC50=10 μg/ml), whereas, methanolic extract inhibited HCT-116 cells (IC50=20 μg/ml). On treating HCT-116 and Caco-2 cells with methanolic and petroleum ether extract respectively in diluted doses to alleviate their cytotoxicity, qRT-PCR showed a significant increase in CK20 expression and a significant decrease in CD44 expression, a significant decrease in Sox-2 and NOTCH-1 expression and a significant increase in PTEN expression. Furthermore, qRT–PCR showed a significant decrease in miR-21-5P and miR-10b-5P expression and significant increase in miR-34a-5P and miR-145 expression. Our results suggest, for the first time, that Jasonia montana methanolic and petroleum ether extracts can induce colorectal CSCs differentiation.

1 September 2017 in European Journal of Cell Biology
Verified
Journal Article
Closed access
DADina AlSadek
Dina AlSadek
Haitham Ali Badr El-Morsi BadrHaitham Ali Badr El-Morsi Badr
Haitham Ali Badr El-Morsi Badr
TATamer A. Al-Shafie
Tamer A. Al-Shafie
Sabry El-BahrSabry El-Bahr
Sabry El-Bahr
MEMotawa E. El-Houseini
Motawa E. El-Houseini
HAhafiz Ahmed
hafiz Ahmed